Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc.

Kepler Capital analyst Alessandro Cuglietta maintained a Buy rating on Abeo SA on May 13 and set a price target of €18.00. The company’s shares clo...

Kepler Capital  Remains a Buy on Abeo SA (4A8)

Oppenheimer analyst reiterated a Buy rating on Abeona Therapeutics today and set a price target of $22.00. In a report released today, H.C. Wainwri...

Abeona Therapeutics (ABEO) Gets a Buy from Oppenheimer

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abeona Therapeutics (ABEO), Protara Therapeutics (TA...

Market Cap	$217.93M	P/E Ratio	N/A
52W High	$7.54	52W Low	$4.00
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	30.9%	52W Position	42.1%
Overall Score	60	Value Score	80
Quality Score	39	Technical Score	63

EPS Current Est	$-0.79	EPS Next Est	$-0.14
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABEO	$5.49	+0.92%	577.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABEO	$5.49	+0.9%	577.30K
3
4
5
6

ABEO

ABEO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Abeona Therapeutics Inc. Data in Excel

Get Abeona Therapeutics Inc. Data in Excel